Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 13, 2006

Ablynx Achieves First Milestone With P&GP

  • Ablynx reached a first milestone in its discovery and development collaboration with Procter & Gamble Pharmaceuticals (P&GP) establishing the potential of Ablynx’ Nanobody® technology for possible new treatments in the musculoskeletal category.

    The Nanobody® technology has been used to rapidly identify a highly diverse and potent panel of Nanobodies® against one of the targets exclusive to the collaboration, triggering a milestone payment. 

    As part of this on-going collaboration Ablynx is responsible for discovering Nanobodies® that meet an agreed product profile. P&GP is responsible for the pre-clinical and clinical development of Nanobodies® as well as the commercialization of any resulting drug products.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »